Alphamab Oncology has announced research updates for their drug JSKN003, which were presented at the 2025 ASCO Annual Meeting held from May 30 to June 3. The updates are based on findings from two clinical studies, JSKN003-101 and JSKN003-102. JSKN003-101 is a first-in-human, open-label, multi-center phase I clinical study conducted in Australia, focusing on patients with advanced or metastatic solid tumors. Meanwhile, JSKN003-102 is a phase I/II clinical study carried out in China, targeting patients with advanced solid tumors. These studies evaluate the efficacy and safety of JSKN003 for various indications. Alphamab Oncology emphasizes its proprietary protein engineering platforms and aims to develop multifunctional biological drug candidates to benefit patients globally. However, the company advises cautious handling of its shares, as successful development and marketing of JSKN003 are not guaranteed.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。